Selected Publications from OnkPat

Denna sida på svenska

OnkPat publications with Impact factor 8 and higher:


Mass cytometry and topological data analysis reveal immune parameters associated with complications after allogeneic stem cell transplantation.
Tadepally Lakshmikanth, Axel Olin, Yang Chen, Jaromir Mikes, Erik Fredlund, Mats Remberger, Brigitta Omazic, Petter Brodin
Cell Reports, online 29 augusti 2017

Distrust in the End-of-Life Care Provided to a Parent and Long-Term Negative Outcomes Among Bereaved Adolescents: A Population-Based Survey Study.
Beernaert K, Kreicbergs U, Fürst C, Nyberg T, Steineck G, Bylund-Grenklo T
J. Clin. Oncol. 2017 Sep;35(27):3136-3142

PHGDH Defines a Metabolic Subtype in Lung Adenocarcinomas with Poor Prognosis.
Zhang B, Zheng A, Hydbring P, Ambroise G, Ouchida A, Goiny M, et al
Cell Rep 2017 Jun;19(11):2289-2303

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades.
Esserman L, Yau C, Thompson C, van 't Veer L, Borowsky A, Hoadley K, et al
JAMA Oncol 2017 Nov;3(11):1503-1510

SOX5/6/21 Prevent Oncogene-Driven Transformation of Brain Stem Cells.
Kurtsdotter I, Topcic D, Karlén A, Singla B, Hagey D, Bergsland M, et al
Cancer Res. 2017 Sep;77(18):4985-4997

Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.
Lalonde E, Alkallas R, Chua M, Fraser M, Haider S, Meng A, et al
Eur. Urol. 2017 Jul;72(1):22-31

Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.
Muranen T, Greco D, Blomqvist C, Aittomäki K, Khan S, Hogervorst F, et al
Genet. Med. 2017 May;19(5):599-603

Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells.
Liu L, Béziat V, Oei V, Pfefferle A, Schaffer M, Lehmann S, et al
Cancer Immunol Res 2017 Aug;5(8):654-665

Converting Adult Pancreatic Islet α Cells into β Cells by Targeting Both Dnmt1 and Arx.
Chakravarthy H, Gu X, Enge M, Dai X, Wang Y, Damond N, et al
Cell Metab. 2017 Mar;25(3):622-634

Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.
Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, et al
JAMA Oncol 2017 Sep;3(9):1204-1212

A multi-step peptidolytic cascade for amino acid recovery in chloroplasts.
Teixeira P, Kmiec B, Branca R, Murcha M, Byzia A, Ivanova A, et al
Nat. Chem. Biol. 2017 Jan;13(1):15-17

BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer.
Shimelis H, Mesman R, Von Nicolai C, Ehlen A, Guidugli L, Martin C, et al
Cancer Res. 2017 Jun;77(11):2789-2799

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.
Leroy B, Ballinger M, Baran-Marszak F, Bond G, Braithwaite A, Concin N, et al
Cancer Res. 2017 Mar;77(6):1250-1260

Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo E, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, et al
Eur. Urol. 2017 May;71(5):776-787

Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia.
Ojamies P, Kontro M, Edgren H, Ellonen P, Lagström S, Almusa H, et al
Leukemia 2017 May;31(5):1048-1058

An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle S, O'Sullivan J, et al
Ann. Oncol. 2017 05;28(5):1090-1097

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.
Eldfors S, Kuusanmäki H, Kontro M, Majumder M, Parsons A, Edgren H, et al
Leukemia 2017 Jan;31(1):51-57

TP53 and 53BP1 Reunited.
Soussi T, Kroemer G
Trends Cell Biol. 2017 May;27(5):311-313

Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma.
Helgadottir H, Kis L, Ljungman P, Larkin J, Kefford R, Ascierto P, et al
Ann. Oncol. 2017 Jul;28(7):1672-1673

Inhibiting the system xC(-)/glutathione axis selectively targets cancers with mutant-p53 accumulation.
Liu D, Duong C, Haupt S, Montgomery K, House C, Azar W, et al
Nat Commun 2017 Mar;8():14844

Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes.
Li J, Ivansson E, Klevebring D, Tobin N, Lindström L, Holm J, et al
Clin. Cancer Res. 2017 May;23(10):2584-2592

Targeted Sequencing Reveals Low-Frequency Variants in EPHA Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy.
Apellániz-Ruiz M, Tejero H, Inglada-Pérez L, Sánchez-Barroso L, Gutiérrez-Gutiérrez G, Calvo I, et al
Clin. Cancer Res. 2017 Mar;23(5):1227-1235

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, et al
Leukemia 2017 May;31(5):1108-1116

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, Kumar A, et al
Leukemia 2017 May;31(5):1187-1195

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long G, Flaherty K, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al
Ann. Oncol. 2017 Jul;28(7):1631-1639

Treatment Restarting After Discontinuation of Adjuvant Hormone Therapy in Breast Cancer Patients.
He W, Smedby K, Fang F, Olsson H, Margolin S, Hall P, et al
J. Natl. Cancer Inst. 2017 10;109(10):

Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy.
Sooriakumaran P, Nyberg T, Akre O, Widmark A, Hamdy F, Graefen M, et al
Eur. Urol. 2017 Sep;72(3):345-351

A Zebrafish Model Discovers a Novel Mechanism of Stromal Fibroblast-Mediated Cancer Metastasis.
Liu C, Zhang Y, Lim S, Hosaka K, Yang Y, Pavlova T, et al
Clin. Cancer Res. 2017 Aug;23(16):4769-4779

Research needs in breast cancer.
Cardoso F, Harbeck N, Barrios C, Bergh J, Cortés J, El Saghir N, et al
Ann. Oncol. 2017 Feb;28(2):208-217

Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.
Stauder R, Eichhorst B, Hamaker M, Kaplanov K, Morrison V, Österborg A, et al
Ann. Oncol. 2017 02;28(2):218-227

Reducing VEGF-B Signaling Ameliorates Renal Lipotoxicity and Protects against Diabetic Kidney Disease.
Falkevall A, Mehlem A, Palombo I, Heller Sahlgren B, Ebarasi L, He L, et al
Cell Metab. 2017 Mar;25(3):713-726

Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.
Taylor C, Correa C, Duane F, Aznar M, Anderson S, Bergh J, et al
J. Clin. Oncol. 2017 May;35(15):1641-1649

Cell of Origin Links Histotype Spectrum to Immune Microenvironment Diversity in Non-small-Cell Lung Cancer Driven by Mutant Kras and Loss of Lkb1.
Nagaraj A, Lahtela J, Hemmes A, Pellinen T, Blom S, Devlin J, et al
Cell Rep 2017 Jan;18(3):673-684

Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer.
Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi J, Yadav B, et al
Eur. Urol. 2017 Mar;71(3):319-327

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.
Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, et al
Leukemia 2017 Jul;31(7):1633-1637

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
Kontro M, Kumar A, Majumder M, Eldfors S, Parsons A, Pemovska T, et al
Leukemia 2017 Feb;31(2):301-309

Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.
Fischer S, Tandstad T, Wheater M, Porfiri E, Fléchon A, Aparicio J, et al
J. Clin. Oncol. 2017 Jan;35(2):194-200

Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.
Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, et al
Cancer Cell 2017 Apr;31(4):576-590.e8

Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.
Erlandsson J, Holm T, Pettersson D, Berglund , Cedermark B, Radu C, et al
Lancet Oncol. 2017 Mar;18(3):336-346

Proteogenomics produces comprehensive and highly accurate protein-coding gene annotation in a complete genome assembly of Malassezia sympodialis.
Zhu Y, Engström P, Tellgren-Roth C, Baudo C, Kennell J, Sun S, et al
Nucleic Acids Res. 2017 Mar;45(5):2629-2643

Estrogen Receptor β as a Therapeutic Target in Breast Cancer Stem Cells.
Ma R, Karthik G, Lövrot J, Haglund F, Rosin G, Katchy A, et al
J. Natl. Cancer Inst. 2017 03;109(3):1-14

Therapeutic implications of tumor interstitial acidification.
Kolosenko I, Avnet S, Baldini N, Viklund J, De Milito A
Semin. Cancer Biol. 2017 Apr;43():119-133

A multi-step peptidolytic cascade for amino acid recovery in chloroplasts.
Teixeira P, Kmiec B, Branca R, Murcha M, Byzia A, Ivanova A, et al
Nat. Chem. Biol. 2017 Jan;13(1):15-17

Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology.
Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, et al
J. Clin. Oncol. 2017 Jan;35(2):254-255

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
Neoptolemos J, Palmer D, Ghaneh P, Psarelli E, Valle J, Halloran C, et al
Lancet 2017 Mar;389(10073):1011-1024

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N, Rudd S, Ljungblad L, Sanjiv K, Myrberg I, Paulin C, et al
Nat. Med. 2017 Feb;23(2):256-263